{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+%28Group+2%29", "query": { "intervention": "Tacrolimus (Group 2)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 77, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tacrolimus+%28Group+2%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T03:31:50.850Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00282230", "title": "A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "FK778", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2003-11", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2012-06-07", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00282230" }, { "nct_id": "NCT01680861", "title": "Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transplant; Failure, Kidney" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Enteric Coated Mycophenolate Sodium (EC-MPS)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gaetano Ciancio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2012-11", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01680861" }, { "nct_id": "NCT00407160", "title": "A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Kidney Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "The University of Texas Medical Branch, Galveston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2004-08", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2019-03-04", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 1, "location_summary": "Galveston, Texas", "locations": [ { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407160" }, { "nct_id": "NCT04280276", "title": "TruGraf Utilization in High IPV Levels", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Transplant; Complications" ], "interventions": [ { "name": "TruGraf test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2020-03-02", "completion_date": "2022-03-01", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04280276" }, { "nct_id": "NCT00506922", "title": "Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Pentostatin", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 150, "start_date": "2000-09", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00506922" }, { "nct_id": "NCT06280950", "title": "Expanding Liver Transplant Immunosuppression Minimization Via Everolimus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus (continued reduction)", "type": "DRUG" }, { "name": "Tacrolimus (maintain 50% reduction)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2024-09-12", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06280950" }, { "nct_id": "NCT01436305", "title": "Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation", "Renal Transplantation" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Basiliximab", "type": "BIOLOGICAL" }, { "name": "Short-term Tac", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "Belatacept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2011-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 3, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01436305" }, { "nct_id": "NCT00448201", "title": "Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 71, "start_date": "2011-01-07", "completion_date": "2012-05-23", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448201" }, { "nct_id": "NCT00374803", "title": "Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End Stage Renal Disease (ESRD)" ], "interventions": [ { "name": "Mycophenolic Acid (Myfortic)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 45, "start_date": "2006-04", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2016-04-28", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00374803" }, { "nct_id": "NCT00866879", "title": "Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplant Rejection" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Demographic Data, Medical History, and Donor Data", "type": "OTHER" }, { "name": "Blood Draws for Control Group", "type": "PROCEDURE" }, { "name": "Blood Draws for Experimental Group", "type": "PROCEDURE" }, { "name": "Donor Blood Draws", "type": "PROCEDURE" }, { "name": "Donor Information", "type": "OTHER" }, { "name": "Kidney Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 275, "start_date": "2007-06", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2019-06-28", "last_synced_at": "2026-09-25T03:31:50.850Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866879" } ] }